Comparing the effects of two different doses of Dexmedetomidine and observing for which dose has a moresignificant decrease in the agitation resulting from Sevoflurane usage in Paediatric patients posted for lower Abdominal Surgeries

Comparison of two different doses of Dexmedetomidine in attenuation of Sevoflurane associated Emergence Agitation in paediatric patients posted for lower abdominal surgeries A Hospital based Randomised Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/066425

Enrollment

Registered

2024-04-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Administration of dexmedetomidine: comparison of two different doses of dexmedetomidine (0.3mcg/kg and 0.5mcg/kg) administered via intravenous route as an infusion over 10 mins to look

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status I and II. Age between 2 to 10 years. Patients undergoing lower abdominal surgeries Operation time less than or equal to 1 hour.

Exclusion criteria

Exclusion criteria: risk of aspiration known difficult airway Patients with Upper respiratory tract infections congenital malformations involving respiratory tract History of epilepsy Patients with cardiac, renal or liver diseases Patients with allergy to the study drug cervical spine disease

Design outcomes

Primary

Measure	Time frame
To compare effects of 0.3 mcg/kg and 0.5mcg/kg of dexmedetomidine in attenuation of emergence agitation in paediatric patient maintained on Sevoflurane, undergoing lower abdominal surgeries.Timepoint: after surgery 10 mins 20 mins 30 mins 40 mins 50 mins 1 hour every 1 hour until 24 hours	—

Secondary

Measure	Time frame
Hemodynamic parameter assessment for 24 hours after administration of study drug.Timepoint: every 1 hour until 24 hours post surgery	—

Countries

India

Contacts

Public ContactDr Mahantesh S Mudakangoudar

KLE Dr. Prabhakar Kore Hospital and MRC

drmontygoudar@yahoo.co.in7829164500

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026